BE2014C002I2 - - Google Patents

Download PDF

Info

Publication number
BE2014C002I2
BE2014C002I2 BE2014C002C BE2014C002C BE2014C002I2 BE 2014C002 I2 BE2014C002 I2 BE 2014C002I2 BE 2014C002 C BE2014C002 C BE 2014C002C BE 2014C002 C BE2014C002 C BE 2014C002C BE 2014C002 I2 BE2014C002 I2 BE 2014C002I2
Authority
BE
Belgium
Application number
BE2014C002C
Other languages
French (fr)
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34975320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C002(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of BE2014C002I2 publication Critical patent/BE2014C002I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
BE2014C002C 2004-03-05 2014-01-16 BE2014C002I2 (pm)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55091504P 2004-03-05 2004-03-05

Publications (1)

Publication Number Publication Date
BE2014C002I2 true BE2014C002I2 (pm) 2024-08-08

Family

ID=34975320

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C002C BE2014C002I2 (pm) 2004-03-05 2014-01-16

Country Status (21)

Country Link
US (11) US7932268B2 (pm)
EP (1) EP1725234B2 (pm)
JP (4) JP5697296B2 (pm)
KR (2) KR101494067B1 (pm)
AU (1) AU2005221656B2 (pm)
BE (1) BE2014C002I2 (pm)
CA (2) CA2558766A1 (pm)
CY (2) CY1114218T1 (pm)
DK (1) DK1725234T4 (pm)
ES (1) ES2399721T5 (pm)
FR (1) FR14C0003I2 (pm)
HR (1) HRP20130115T4 (pm)
LT (1) LTC1725234I2 (pm)
ME (1) ME02070B (pm)
NL (1) NL300634I2 (pm)
NZ (1) NZ549721A (pm)
PL (1) PL1725234T5 (pm)
PT (1) PT1725234E (pm)
RS (1) RS52825B2 (pm)
SI (2) SI1725234T1 (pm)
WO (1) WO2005087234A1 (pm)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52825B2 (sr) 2004-03-05 2018-03-30 Univ Pennsylvania Postupci za lečenje poremećaja ili bolesti povezanih sa hiperlipidemijom i hiperholesterolemijom uz minimizaciju sporednih efekata
JP2009511634A (ja) * 2005-10-18 2009-03-19 エージェリオン ファーマシューティカルズ 哺乳動物において高脂血症に関連する障害を治療する方法
JP2010502702A (ja) * 2006-09-05 2010-01-28 シェーリング コーポレイション 脂質管理およびアテローム性動脈硬化症および脂肪肝の治療治療において使用される医薬組成物
WO2008072056A1 (en) * 2006-12-14 2008-06-19 Pfizer Limited Use of mtp inhibitors for the treatment of obesity using low doses and dose-escalation
AU2007338625A1 (en) * 2006-12-21 2008-07-03 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor
JP5875097B2 (ja) * 2009-12-11 2016-03-02 学校法人東邦大学 脂質取り込み抑制剤
AU2014353246A1 (en) 2013-11-20 2016-06-16 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
CN103690960A (zh) * 2013-12-18 2014-04-02 北京科源创欣科技有限公司 甲磺酸洛美他派药物组合物及制备方法
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
MX367478B (es) 2014-03-20 2019-08-23 Cymaby Therapeutics Inc Tratamiento de enfermedades colestasicas intrahepaticas.
AU2015243239B2 (en) 2014-04-11 2019-11-14 Cymabay Therapeutics, Inc. Treatment of NAFLD and NASH
BR102015025502B1 (pt) * 2015-04-30 2022-06-21 Aegerion Pharmaceuticals, Inc Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição
WO2016181409A1 (en) 2015-05-11 2016-11-17 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome -
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
KR20210010890A (ko) * 2018-05-16 2021-01-28 립 테라퓨틱스, 엘엘씨 Pcsk9 결합 분자를 포함하는 조성물 및 사용 방법
JP2023536855A (ja) * 2020-07-29 2023-08-30 アムリット・ファーマシューティカルズ・インコーポレイテッド 小児患者における高脂血症及び高コレステロール血症の治療方法における使用のためのロミタピド
BR112023016943A2 (pt) 2021-03-03 2023-10-31 Amryt Pharmaceuticals Inc Métodos para tratamento da síndrome de quilomicronemia familiar

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1722496A (en) 1926-07-29 1929-07-30 William B Chapman Boiler and method of operating the same
US1725396A (en) 1927-05-16 1929-08-20 Int Harvester Co Plow
US1725496A (en) 1927-12-27 1929-08-20 John R Ketchum Oil-well pump
US2821696A (en) 1953-11-25 1958-01-28 Hughes Aircraft Co Electronic multiple comparator
JPS5612114B2 (pm) 1974-06-07 1981-03-18
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US4499289A (en) * 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) * 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
DE3581638D1 (de) 1984-12-04 1991-03-07 Sandoz Ag Inden-analoga von mevalonolakton und ihre derivate.
US4668794A (en) 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
KR900001212B1 (ko) 1985-10-25 1990-02-28 산도즈 파마슈티칼스 코오포레이숀 메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도
FR2596393B1 (fr) 1986-04-01 1988-06-03 Sanofi Sa Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
US4716175A (en) 1987-02-24 1987-12-29 Warner-Lambert Company Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol acyltransferase
NZ224733A (en) 1987-05-22 1990-12-21 Squibb & Sons Inc Organophosphorus hmg-coa reductase inhibitors; intermediates and compositions thereof
US5015644A (en) 1987-06-02 1991-05-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds
US4924024A (en) 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
US4871721A (en) * 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
NO177005C (no) 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
KR930005040B1 (ko) * 1989-08-31 1993-06-12 주식회사 금성사 식기 건조기 겸용 전자레인지 및 그 구동제어방법
US5026554A (en) 1990-09-13 1991-06-25 Merck & Co., Inc. Method of inhibiting fungal growth using squalene synthetase inhibitors
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
CA2091102C (en) 1992-03-06 2009-05-26 John R. Ii Wetterau Microsomal triglyceride transfer protein
US5470845A (en) * 1992-10-28 1995-11-28 Bristol-Myers Squibb Company Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
DE4435477A1 (de) 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
US5510379A (en) 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
US5536859A (en) 1995-02-27 1996-07-16 Amoco Corporation Alpha-olefin catalyst and process
GB9504066D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Phosphate derivatives of ureas and thioureas
EP1181954A3 (en) 1995-06-07 2002-08-21 Pfizer Inc. Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (ApoB) secretion
EP0832069B1 (en) 1995-06-07 2003-03-05 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
DE19546919A1 (de) * 1995-12-15 1997-06-19 Bayer Ag N-Heterocyclisch substituierte Phenylessigsäure-Derivate
DE19546918A1 (de) * 1995-12-15 1997-06-19 Bayer Ag Bicyclische Heterocyclen
DE19613550A1 (de) 1996-04-04 1997-10-09 Bayer Ag Neue Pyrimido[1,2-a]indole
DE19613549A1 (de) * 1996-04-04 1997-10-09 Bayer Ag Verfahren zur Herstellung von enantiomerenreinen Cycloalkano-indol- und azaindol-carbonsäuren und deren aktivierte Derivate
US6774236B1 (en) * 1996-04-04 2004-08-10 Bayer Aktiengesellschaft Process for the preparation of enantiomerically pure cycloalkano-indol -and azaindol -and pyrimido [1,2A]indolcarbocyclic acids and their activated derivatives
DE19615265A1 (de) * 1996-04-18 1997-12-04 Bayer Ag Neue Pyridazino-, Pyrimido-, Pyrazino- und Triazino-indole
DE69715188T2 (de) 1996-04-30 2003-01-02 Pfizer Inc., New York Verfahren und zwischenprodukte zur herstellung von 4-trifluoromethylbiphenyl-2-carbonsaüre,(2-(2h-(1,2,4) triazol-3-ylmethyl)-1,2,3,4-tetrahydro-isoquinolin-6-yl)-amide
US6057339A (en) * 1996-05-09 2000-05-02 Bristol-Myers Squibb Company Method of inhibiting or treating phytosterolemia with an MTP inhibitor
US5827875A (en) * 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5885983A (en) * 1996-05-10 1999-03-23 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5883109A (en) * 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
JP2002513379A (ja) 1996-07-24 2002-05-08 ブリストル―マイヤーズ・スクイブ・カンパニー Ｍｔｐ抑制因子を用いる、高ｌｄｌの必要を持つ腫瘍の治療法
CN1238764A (zh) 1996-11-27 1999-12-15 美国辉瑞有限公司 可抑制ApoB－分泌物/MTP的酰胺
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
AU5513298A (en) 1996-12-20 1998-07-17 Bristol-Myers Squibb Company Heterocyclic inhibitors of microsomal triglyceride transfer protein and method
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
EP0989852A4 (en) 1997-01-17 2002-11-13 Bristol Myers Squibb Co METHODS FOR TREATING ATHEROSCLEROSE THROUGH AN MPT INHIBITOR AND CHOLESTEROL LEVELS LOWERING MEDICINES
WO1998031225A1 (en) 1997-01-17 1998-07-23 Bristol-Myers Squibb Company A method of inhibiting or treating phytosterolemia with an mtp inhibitor
EP1024804A4 (en) 1997-05-01 2001-03-21 Bristol Myers Squibb Co MTP INHIBITORS AND FAT-SOLUBLE VITAMIN THERAPEUTICS TO REDUCE SERUM LIPIDS
US5990110A (en) * 1997-07-15 1999-11-23 Bristol-Meyers Squibb Company Method for treating tumors having high LDL requirements employing MTP inhibitors
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
US20020045271A1 (en) * 1998-06-10 2002-04-18 Licata And Tyrrell P.C. Compounds and methods for identifying compounds that interact with microsomal triglyceride transfer protein binding sites on apolipoprotein b and modulate lipid biosynthesis
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
EE04356B1 (et) * 1998-09-17 2004-10-15 Bristol-Myers Squibb Company aP2 inhibiitor kasutamiseks suhkurtõve ravis ja seda sisaldav ravimkoostis
US7358254B2 (en) 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
IL133201A0 (en) 1998-12-04 2001-03-19 Pfizer Prod Inc Lowering blood levels of lipoproten (a)
WO2000038725A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations for cardiovascular indications
EP1156803A4 (en) * 1999-02-09 2004-03-17 Bristol Myers Squibb Co FXA LACTAM INHIBITORS AND METHOD
US6344450B1 (en) * 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
DE60018225T2 (de) * 1999-03-01 2005-12-29 Pfizer Products Inc., Groton Oxamsäuren mit einer Cyanogruppe als Liganden für den Thyroidrezeptor
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
AU5200299A (en) 1999-07-30 2001-02-19 Hendrik Jan Verkade A method to increase the excretion of non-sterol endogenous hydrophobic substances by increasing excretion of fat via the faeces
DE19951022A1 (de) 1999-10-22 2001-04-26 Bayer Ag Carbolinderivate
IL139450A0 (en) 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US6812345B2 (en) * 2000-06-15 2004-11-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US6627636B2 (en) * 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
DE10030375A1 (de) * 2000-06-21 2002-01-03 Bayer Ag Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
US6649770B1 (en) 2000-11-27 2003-11-18 Ciba Specialty Chemicals Corporation Substituted 5-aryl-2-(2-hydroxyphenyl)-2H-benzotriazole UV absorbers, compositions stabilized therewith and process for preparation thereof
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
JP2002220345A (ja) 2001-01-24 2002-08-09 Sumitomo Pharmaceut Co Ltd 脂肪肝改善剤
PL369033A1 (en) * 2001-01-26 2005-04-18 Schering Corporation Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
CN1522246B (zh) * 2001-06-28 2010-04-21 辉瑞产品公司 三酰胺取代的吲哚、苯并呋喃及苯并噻吩
US6884812B2 (en) * 2001-08-31 2005-04-26 Aventis Pharma Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
AU2002357137A1 (en) * 2001-12-10 2003-06-23 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
US20030162788A1 (en) * 2002-01-10 2003-08-28 Boehringer Ingelheim Pharma Kg Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals
IL161134A0 (en) * 2002-02-28 2004-08-31 Japan Tobacco Inc Ester compound and medical use thereof
JP3662566B2 (ja) * 2002-02-28 2005-06-22 日本たばこ産業株式会社 エステル化合物及びその医薬用途
PL375230A1 (en) * 2002-07-09 2005-11-28 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
DE60325370D1 (de) 2002-07-23 2009-01-29 Basf Se Synergistische herbizide zusammensetzungen
WO2004028544A1 (en) 2002-09-25 2004-04-08 Novo Nordisk A/S Use of mas-compounds for treating diseases associated with lipid metabolism
US20050090426A1 (en) * 2003-03-24 2005-04-28 Blumberg Richard S. Methods of inhibiting inflammation
US6846836B2 (en) * 2003-04-18 2005-01-25 Bristol-Myers Squibb Company N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
EP1635832A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes
US20060160834A1 (en) 2003-06-06 2006-07-20 Fong Tung M Combination therapy for the treatment of hypertension
WO2005000217A2 (en) 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
US20040253923A1 (en) * 2003-06-12 2004-12-16 Braley Richard C. System and method for electronically pairing devices
JP2007508241A (ja) 2003-07-31 2007-04-05 バイエル・フアーマシユーチカルズ・コーポレーシヨン Ｐｄｅ１０ａ阻害剤を用いる糖尿病および関連障害の処置方法
WO2005018436A2 (en) * 2003-08-26 2005-03-03 The Trustees Of Boston University Methods for the diagnosis, prognosis and treatment of metabolic syndrome
EP1669345A4 (en) * 2003-08-29 2008-02-20 Japan Tobacco Inc ESTER DERIVATIVE AND MEDICAL USE THEREOF
US7153976B2 (en) 2003-10-06 2006-12-26 Pfizer Inc. Purification process for an azabicyclo[3.1.0]hexane compound
EP1522541A1 (en) 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
AU2004279855A1 (en) * 2003-10-08 2005-04-21 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters containing cycloalkyl or pyranyl groups
DE602004020649D1 (de) * 2003-11-07 2009-05-28 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
WO2005051382A1 (ja) 2003-11-28 2005-06-09 Astellas Pharma Inc. 脂質低下作用増強剤
JP2007519605A (ja) 2004-01-30 2007-07-19 日本たばこ産業株式会社 食欲抑制薬
US20070098778A1 (en) 2004-03-02 2007-05-03 Abeille Pharmaceuticals, Inc. Co-formulations or kits of bioactive agents
RS52825B2 (sr) * 2004-03-05 2018-03-30 Univ Pennsylvania Postupci za lečenje poremećaja ili bolesti povezanih sa hiperlipidemijom i hiperholesterolemijom uz minimizaciju sporednih efekata
WO2005085466A2 (en) 2004-03-09 2005-09-15 Bayer Healtcare Ag Diagnostic and therapeutics for diseases associated with rho-associated protein kinase 2 (rock2)
GB0405459D0 (en) 2004-03-11 2004-04-21 Shea Clayton O Skipping ropes
WO2005094864A2 (en) 2004-03-30 2005-10-13 Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. Treatment of hedgehog- and wnt-secreting tumors with inhibitors of lipoprotein particle biogenesis
JP2008504229A (ja) 2004-04-09 2008-02-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 過剰体重および肥満症患者のための間欠的投薬レジメン
JP4782991B2 (ja) 2004-06-30 2011-09-28 株式会社東芝 情報処理機器および情報処理機器の表示制御方法
AU2005259864A1 (en) * 2004-06-30 2006-01-12 Combinatorx, Incorporated Methods and reagents for the treatment of metabolic disorders
CA2582767C (en) * 2004-10-25 2011-05-24 Japan Tobacco Inc. Solid formulation with improved solubility and stability and method for producing said formulation
EA014420B1 (ru) * 2004-12-06 2010-12-30 Релайэнт Фармасьютикалз, Инк. Омега-3 жирные кислоты и дислипидемический агент для липидной терапии
BRPI0518616A (pt) * 2004-12-08 2008-01-15 Sirion Therapeutics Inc métodos para tratar doenças relacionadas com retinol, degeneração ou distrofia macular e diabetes tipo i ou tipo ii
US20060252733A1 (en) 2005-04-07 2006-11-09 Novelix Pharmaceuticals, Inc. Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism
WO2006108666A1 (en) 2005-04-13 2006-10-19 Proteosys Ag Mefloquine, nelfinavir and saquinavir as novel agents for neurodegenerative and (neuro-) inflammatory diseases
FR2884831B1 (fr) 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si Methode de criblage de composes inhibiteurs de la mtp
WO2006129193A2 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
JP2009507813A (ja) 2005-09-13 2009-02-26 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト 殺有害生物剤ビ−フェニル−アミジン誘導体
JP2009511634A (ja) * 2005-10-18 2009-03-19 エージェリオン ファーマシューティカルズ 哺乳動物において高脂血症に関連する障害を治療する方法
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
JP2009537505A (ja) 2006-05-18 2009-10-29 バイエル・ヘルスケア・アクチェンゲゼルシャフト インプリタピドを含む薬学的組成物およびこの薬学的組成物の使用方法
US20090042835A1 (en) 2006-06-02 2009-02-12 Davis Roger A Compositions and methods for ameliorating hyperlipidemia
AU2007254827A1 (en) 2006-06-02 2007-12-13 San Diego State University Research Foundation Compositions and methods for ameliorating hyperlipidemia
JP2009539885A (ja) 2006-06-13 2009-11-19 メルク フロスト カナダ リミテツド ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのアザシクロペンタン誘導体
US20080016127A1 (en) 2006-06-30 2008-01-17 Microsoft Corporation Utilizing software for backing up and recovering data
DE102006034907A1 (de) 2006-07-28 2008-01-31 Carl Zeiss Microimaging Gmbh Laser-Scanning-Mikroskop
US20080033019A1 (en) 2006-08-07 2008-02-07 Duke University Cholesterol lowering drug combination
US20100310553A1 (en) 2006-08-14 2010-12-09 Guangxiang Luo Compositions and Methods for Controlling Hepatitis C Virus Infection
JP2010502702A (ja) 2006-09-05 2010-01-28 シェーリング コーポレイション 脂質管理およびアテローム性動脈硬化症および脂肪肝の治療治療において使用される医薬組成物
WO2008072061A1 (en) 2006-12-14 2008-06-19 Pfizer Products Inc. Method of treatment of obesity with an mtp inhibitor in conjunction with an increased-fat diet
WO2008075949A1 (en) 2006-12-20 2008-06-26 Friesland Brands B.V. Modulation of human microsomal triglyceride transfer protein (mtp or mttp) gene expression by food-grade/ingested dietary microorganisms
AU2007338625A1 (en) 2006-12-21 2008-07-03 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor
US7645732B2 (en) 2007-01-24 2010-01-12 Board Of Regents, The University Of Texas System Treating hepatitis C virus infection
WO2008090198A1 (en) 2007-01-25 2008-07-31 Janssen Pharmaceutica Nv Use of mtp inhibitors for increasing levels of satiety hormones
WO2008115574A1 (en) 2007-03-21 2008-09-25 Reliant Pharmaceuticals, Inc. Cb1 antagonist and a dyslipidemic agent and/or metabolic regulator, and methods of making and using same
FR2922945B1 (fr) 2007-10-31 2009-11-27 Peugeot Citroen Automobiles Sa Procede de determination d'intervalle de maintenance pour vehicule automobile.
WO2010083280A2 (en) 2009-01-14 2010-07-22 Aegerion Pharmaceuticals, Inc. Methods for treating obesity and disorders associated with hyperlipidemia in a mammal
US9069114B2 (en) 2010-07-23 2015-06-30 Prysmian S.P.A. Bend-resistant single-mode optical fibre

Also Published As

Publication number Publication date
HRP20130115T1 (hr) 2013-03-31
JP5902760B2 (ja) 2016-04-13
CA2910191C (en) 2022-03-08
EP1725234B1 (en) 2012-11-21
LTC1725234I2 (lt) 2016-11-10
CY1114218T1 (el) 2015-12-09
KR20060129082A (ko) 2006-12-14
DK1725234T4 (en) 2016-05-09
ES2399721T5 (es) 2016-05-25
NZ549721A (en) 2010-08-27
JP2012232995A (ja) 2012-11-29
US9861622B2 (en) 2018-01-09
PT1725234E (pt) 2013-03-04
US20160081994A1 (en) 2016-03-24
FR14C0003I2 (fr) 2015-05-01
US9265758B2 (en) 2016-02-23
US20180318278A1 (en) 2018-11-08
US8618135B2 (en) 2013-12-31
JP6189918B2 (ja) 2017-08-30
US11554113B2 (en) 2023-01-17
CY2014007I1 (el) 2015-12-09
US10016404B2 (en) 2018-07-10
JP2007527433A (ja) 2007-09-27
NL300634I2 (pm) 2016-09-22
AU2005221656B2 (en) 2011-06-23
AU2005221656A1 (en) 2005-09-22
EP1725234B9 (en) 2013-04-10
ME02070B (me) 2013-10-31
US20160331739A1 (en) 2016-11-17
RS52825B2 (sr) 2018-03-30
US20230109871A1 (en) 2023-04-13
JP5697296B2 (ja) 2015-04-08
JP2016135762A (ja) 2016-07-28
KR20130004942A (ko) 2013-01-14
US20090042941A1 (en) 2009-02-12
US20230381166A1 (en) 2023-11-30
US7932268B2 (en) 2011-04-26
EP1725234A1 (en) 2006-11-29
PL1725234T5 (pl) 2016-06-30
CA2910191A1 (en) 2005-09-22
JP2014208683A (ja) 2014-11-06
WO2005087234A1 (en) 2005-09-22
FR14C0003I1 (pm) 2014-02-21
US9433617B1 (en) 2016-09-06
CA2558766A1 (en) 2005-09-22
CY2014007I2 (el) 2015-12-09
SI1725234T1 (sl) 2013-04-30
SI1725234T2 (sl) 2016-05-31
HRP20130115T4 (hr) 2016-04-22
US20140303209A1 (en) 2014-10-09
US20120010243A1 (en) 2012-01-12
ES2399721T3 (es) 2013-04-03
US9364470B2 (en) 2016-06-14
EP1725234A4 (en) 2009-04-15
US20210205287A1 (en) 2021-07-08
RS52825B (en) 2013-10-31
US10555938B2 (en) 2020-02-11
DK1725234T3 (da) 2013-02-18
KR101494067B1 (ko) 2015-02-16
US20160256446A1 (en) 2016-09-08
US20170258776A1 (en) 2017-09-14
EP1725234B2 (en) 2016-02-24
PL1725234T3 (pl) 2013-05-31

Similar Documents

Publication Publication Date Title
BE2024C508I2 (pm)
BE2022C549I2 (pm)
BE2023C542I2 (pm)
BE2021C001I2 (pm)
BE2020C513I2 (pm)
BE2020C517I2 (pm)
BE2019C540I2 (pm)
BE2019C523I2 (pm)
BE2019C506I2 (pm)
BE2019C548I2 (pm)
BE2018C045I2 (pm)
BE2020C525I2 (pm)
BE2017C063I2 (pm)
BE2017C027I2 (pm)
BE2017C023I2 (pm)
BE2017C002I2 (pm)
BE2014C071I2 (pm)
BE2014C064I2 (pm)
BE2013C021I2 (pm)
BE2012C025I2 (pm)
BE2019C535I2 (pm)
IN2010KO00412A (pm)
NL300634I2 (pm)
BE2015C011I2 (pm)
BE2012C019I2 (pm)